What is claimed is:

1. A stable liquid pharmaceutical formulation comprising an anti-α4β7 antibody at a concentration of about 100 mg/ml to about 180 mg/ml, citrate, histidine and/or arginine and polysorbate 80, wherein the anti-α4β7 antibody is an IgG1 isotype comprising a light chain variable region comprising a CDR1 comprising SEQ ID NO: 11, a CDR2 comprising SEQ ID NO: 12, and a CDR3 comprising SEQ ID NO: 13, and comprising a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO: 9, and a CDR3 comprising SEQ ID NO: 10, wherein the formulation has a pH of 6 to 7, and wherein the formulation has greater than or equal to 95% monomeric anti-α4β7 antibody as determined by size exclusion chromatography (SEC) after storage at 40ºC for 4 weeks.

2. The stable liquid pharmaceutical formulation of claim 1, wherein the molar ratio of the anti-α4β7 antibody to citrate is about 1:4 to about 1:100.

3. The stable liquid pharmaceutical formulation of claim 1, wherein the molar ratio of citrate to the polysorbate 80 is about 3:1 to about 156:1.

4. A stable liquid pharmaceutical formulation comprising an anti-α4β7 antibody at a concentration of about 100 mg/ml to about 180 mg/ml, citrate, histidine, arginine, and polysorbate 80, wherein the anti-α4β7 antibody comprises a light chain variable region comprising a CDR1 comprising SEQ ID NO: 11, a CDR2 comprising SEQ ID NO: 12, and a CDR3 comprising SEQ ID NO: 13, and comprises a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO: 9, and a CDR3 comprising SEQ ID NO: 10, wherein the formulation has a pH of 6 to 7, and wherein the formulation has greater than or equal to 95% monomeric anti-α4β7 antibody as determined by SEC after storage at 40ºC for 4 weeks.

5. The stable liquid pharmaceutical formulation of claim 1, wherein said antibody is vedolizumab.

6. The stable liquid pharmaceutical formulation of claim 4, wherein said antibody is vedolizumab.

7. The stable liquid pharmaceutical formulation of claim 1, wherein the concentration of citrate is 20 mM to 30 mM.

8. The stable liquid pharmaceutical formulation of claim 1, wherein the concentration of arginine is 50 mM to 150 mM.

9. The stable liquid pharmaceutical formulation of claim 1, comprising histidine and arginine.

10. The stable liquid pharmaceutical formulation of claim 9, wherein the concentration of histidine is 25 mM to 65 mM.

11. The stable liquid pharmaceutical formulation of claim 1, wherein the heavy chain variable region comprises amino acids 20-140 of SEQ ID NO:2 and the light chain variable region comprises amino acids 20-131 of SEQ ID NO:4.

12. The stable liquid pharmaceutical formulation of claim 1, wherein said formulation has a pH between 6.2 and 6.8.

13. The stable liquid pharmaceutical formulation of claim 1, wherein there is < 2.5% aggregate antibody.

14. A stable liquid pharmaceutical formulation comprising about 140 mg/ml to about 170 mg/ml of an anti-α4β7 antibody, about 20 mM to about 30 mM citrate, about 10 mM to about 75 mM histidine, about 0.01% to about 0.5% polysorbate 80, and about 50 mM to about 150 mM arginine, wherein the anti-α4β7 antibody is an IgG1 isotype comprising a light chain variable region comprising a CDR1 comprising SEQ ID NO:11, a CDR2 comprising SEQ ID NO: 12, and a CDR3 comprising SEQ ID NO: 13, and comprising a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO: 9, and a CDR3 comprising SEQ ID NO: 10, wherein the formulation has a pH of 6.1 to 6.9, and wherein the formulation has greater than or equal

to 95% monomeric anti-α4β7 antibody as determined by SEC after storage at 40ºC for 4 weeks.

15. The stable liquid pharmaceutical formulation of claim 14, wherein the heavy chain variable region comprises amino acids 20-140 of SEQ ID NO:2 and the light chain variable region comprises amino acids 20-131 of SEQ ID NO:4.

16. The stable liquid pharmaceutical formulation of claim 14, wherein said antibody is vedolizumab.

17. The stable liquid pharmaceutical formulation of claim 1, wherein after 12 months at 5°C the stable liquid pharmaceutical formulation has less than about 1.0% antibody aggregate formation.

18. The stable liquid pharmaceutical formulation of claim 4, wherein the heavy chain variable region comprises amino acids 20-140 of SEQ ID NO:2 and the light chain variable region comprises amino acids 20-131 of SEQ ID NO:4.

19. The stable liquid pharmaceutical formulation of claim 4, comprising a dose of 108 mg of the anti-α4β7 antibody.

20. The stable liquid pharmaceutical formulation of claim 1, comprising a dose of 108 mg of the anti-α4β7 antibody.

21. The stable liquid pharmaceutical formulation of claim 1, wherein the molar ratio of the polysorbate 80 to the anti-α4β7 antibody is 0.7:1 to 2.0:1.

22. The stable liquid pharmaceutical formulation of claim 14, comprising a dose of 108 mg of the anti-α4β7 antibody.

23. The stable liquid pharmaceutical formulation of claim 4, comprising 150 mg/ml to 170 mg/ml of the anti-α4β7 antibody, wherein the antibody is an IgG1 isotype.

24. The stable liquid pharmaceutical formulation of claim 4, wherein the concentration of histidine is about 25 mM to about 50 mM.

25. The stable liquid pharmaceutical formulation of claim 24, wherein the concentration of arginine is 50 mM to 150 mM.

26. The stable liquid pharmaceutical formulation of claim 24, wherein the concentration of citrate is about 5 mM to about 50 mM.

27. The stable liquid pharmaceutical formulation of claim 1, comprising 0.1% to 0.3% (w/v) polysorbate 80.

28. A stable liquid pharmaceutical formulation comprising an anti-α4β7 antibody at a concentration of about 100 mg/ml to about 180 mg/ml, citrate, histidine and/or arginine, and polysorbate 80, wherein the anti-α4β7 antibody comprises a light chain variable region comprising a CDR1 comprising SEQ ID NO: 11, a CDR2 comprising SEQ ID NO: 12, and a CDR3 comprising SEQ ID NO: 13, and comprises a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO: 9, and a CDR3 comprising SEQ ID NO: 10.

29. The stable liquid pharmaceutical formulation of claim 28, wherein said antibody is vedolizumab.

30. The stable liquid pharmaceutical formulation of claim 28, wherein the concentration of citrate is 20 mM to 30 mM.

31. The stable liquid pharmaceutical formulation of claim 28, wherein the concentration of arginine is 50 mM to 150 mM.

32. The stable liquid pharmaceutical formulation of claim 28, wherein the concentration of histidine is 25 mM to 65 mM.

33. The stable liquid pharmaceutical formulation of claim 28, wherein the heavy chain variable region comprises amino acids 20-140 of SEQ ID NO:2 and the light chain variable region comprises amino acids 20-131 of SEQ ID NO:4.

34. The stable liquid pharmaceutical formulation of claim 28, wherein said formulation has a pH between 6.2 and 6.8.

35. The stable liquid pharmaceutical formulation of claim 28, wherein there is < 2.5% aggregate antibody.